The pre-market decline of Novo Nordisk's US stock market narrowed to 20%, after a sharp drop of nearly 30% at one point, marking the largest single day decline on record, as the trial results of Novo ...

On December 16th, Novo Nordisk announced plans to invest 8.5 billion Danish kroner to establish a new production base in Odense, Denmark. This investment marks the first time in this century that Nov ...

On December 14th local time, Novo Nordisk announced that all regulatory delivery conditions related to its major shareholder Novo Nordisk's $16.5 billion acquisition of US contract pharmaceutical com ...

As one of the leading players in the weight loss drug market, the underperformance of Zepbound, a heavyweight weight loss drug under Eli Lilly and Company (LLY.US), in the third quarter has raised co ...

The safety issues of compound generic drugs of semaglutide preparations are attracting attention. At the beginning of this month, the FDA (US Food and Drug Administration) warned that on August 14th ...

China Net Finance, November 7th (Reporter Chen Qiong) On November 6th, Novo Nordisk held the launch ceremony of "Healthy China Action - Metabolic Renewal Year" at the Novo Nordisk booth at the 7th Ch ...

Novo Nordisk has reached a settlement with Mylan Pharmaceuticals regarding the patent dispute over the weight loss drugs Ozempic and Wegovy. Novo Nordisk and Mylan Pharmaceuticals, a subsidiary of Vi ...

On October 5th, according to Southern Finance, Danish pharmaceutical company Novo Nordisk announced on Friday that it will invest 864 million Brazilian reals ($158.2 million) to renovate a factory in ...

Danish pharmaceutical company Novo Nordisk announced on Friday that it will invest 864 million Brazilian reals ($158.2 million) to renovate a factory in Brazil that produces a quarter of Novo Nordisk ...

[The US Senate questioned that the "weight-loss wonder drug" was overpriced. Novo and Nordisk responded that it was useless to cut the price.] On Tuesday (September 24), the CEO of Danish pharmaceuti ...

According to the website of the United States Senate, the Senate will hold a hearing on September 24 local time to examine whether Novo Nordisk provides overpriced smeglutide products Ozempic and Weg ...

According to analysts from Morningstar and Pitchbook, it is estimated that there will be 16 new GLP-1 drugs launched in the weight loss drug market by 2029, competing for the lucrative market current ...

Reporter Chen Xing On August 7th, Novo Nordisk announced its H1 2024 results that the Phase III OASIS 4 study on weight loss with oral semaglutide Rybelsus (25mg) has been successfully completed. Ora ...

On August 7, 2024, Novo Nordisk released its financial report for the first half of 2024, with operating revenue of 133.4 billion Danish kroner (DKK), equivalent to 19.5 billion US dollars, a year-on ...

On August 7th, Novo Nordisk's US stock market fell more than 5% in pre-market trading, after lowering its profit expectations.

On June 27th, it was reported in the market that the "weight loss miracle drug" Wegovy (Chinese product name: Nuoheying) will be sold in limited quantities in China. On June 28th, relevant personnel ...

21st Century Business Herald reporter Ji Yuanyuan reports from Shanghai Recently, the first injectable version of Smegglutide for long-term weight management, Novoying&Co., Ltd; reg; Finally, it was ...

On June 4th, Novo Nordisk China told reporters that according to approved US prescription information or EU product feature summaries, sexual dysfunction is not a side effect mentioned in the Wegovy ...

With a thematic investment fund betting on the long-term explosive potential of the GLP-1 track sparking discussions, the US stock market is also starting to examine which pharmaceutical companies be ...

On May 21, the GIP/GLP-1 receptor dual agonist tirzepatide of Eli Lilly was approved by the National Drug Administration (NMPA) of China to treat adult type 2 diabetes patients for blood glucose cont ...